Edition:
United States

I'rom Group Co Ltd (2372.T)

2372.T on Tokyo Stock Exchange

1,455JPY
7:35pm EST
Change (% chg)

¥-34 (-2.28%)
Prev Close
¥1,489
Open
¥1,500
Day's High
¥1,509
Day's Low
¥1,452
Volume
41,500
Avg. Vol
114,122
52-wk High
¥1,940
52-wk Low
¥676

Latest Key Developments (Source: Significant Developments)

I'rom Group unit forms business alliance with KKR
Wednesday, 26 Oct 2016 09:47pm EDT 

I'rom Group Co Ltd <2372.T> :Says its unit forms a business alliance with Federation of National Public Service Personnel Aid Associations (KKR), to support on clinical study net work business for KKR's hospital facilities.  Full Article

I'rom Group unit announces success in production process of retinal pigment degeneration treatment
Tuesday, 19 Jul 2016 09:35pm EDT 

I'rom Group Co Ltd <2372.T>:Says its wholly owned unit announced success in production process of retinal pigment degeneration treatment, under cooperation with Kyushu University.  Full Article

I'rom Group unit ID Pharma to grant technology license to KOHJIN BIO
Tuesday, 12 Jul 2016 03:16am EDT 

I'rom Group Co Ltd <2372.T>:Says unit ID Pharma to grant non-exclusive rights in Japan regarding technology license for cancer treatment by amplifing dendritic cells, to Japan-based co KOHJIN BIO.  Full Article

I'rom Group unit gets license for improvement of iPS cell preparation technology in China
Wednesday, 8 Jun 2016 10:36pm EDT 

I'rom Group Co Ltd <2372.T>:Says its unit ID Pharma received license for improvement of iPS cell preparation technology in China.  Full Article

I'rom Group says change of corporate auditor
Tuesday, 24 May 2016 05:05am EDT 

I'rom Group Co Ltd <2372.T>: Says it appoints Avantia GP as corporate auditor to replace PricewaterhouseCoopers Aarata .Says effective date on June 28.  Full Article

I'rom Group establishes jv in Japan
Monday, 23 May 2016 04:11am EDT 

I'rom Group Co Ltd <2372.T>: Says it established a jv named I’rom NA Co., Ltd. in Japan with a Japan-based pharmacy company . Says the jv to be engaged in Site Management Organization .Says the co to hold 70 percent stake in the jv.  Full Article

I’rom Group lowers consolidated full-year outlook for FY 2016
Sunday, 1 May 2016 11:45pm EDT 

I’rom Group Co.,Ltd:Says the company lowered the consolidated full-year outlook for the FY ended March 2016.Revenue forecast decreased to 4,110 million yen from 5,300 million yen.Operating profit forecast decreased to a loss of 480 million yen from a loss of 130 million yen.Ordinary profit forecast decreased to a loss of 810 million yen from a loss of 350 million yen.Net profit forecast decreased to a loss of 870 million yen from 40 million yen.Earnings per share decreased to a loss of 81.99 yen from 3.77 yen.Comments that delay of orders and transactions are the main reasons for the forecast.  Full Article

I’rom Group unit signs iPS cell preparation technology implementation promise contract
Thursday, 31 Mar 2016 02:30am EDT 

I’rom Group Co.,Ltd:Wholly owned subsidiary ID Pharma signed iPS cell preparation technology implementation promise contract with U.S-based company StemoniX to grant non-exclusive rights in U.S.  Full Article

I’rom Group subsidiary receives improvement patent license in Japan
Tuesday, 8 Mar 2016 03:20am EST 

I’rom Group Co.,Ltd:Says subsidiary ID Pharma received improvement patent license in Japan for their sendai virus vector based iPSC production method.  Full Article

I’rom Group lowers consolidated full-year profit outlook for FY 2016
Thursday, 12 Nov 2015 03:30am EST 

I’rom Group Co.,Ltd:Says the company reaffirmed the consolidated full-year outlook for revenue at 5,300 mln yen for the fiscal year ending March 2016.Sees a decrease of operating profit forecast to a loss of 130 mln yen from 70 mln yen.Sees a decrease of ordinary profit forecast to a loss of 350 mln yen from 120 mln yen.Sees a decrease of net profit forecast to 40 mln yen from 530 mln yen.Sees a decrease of earnings per share to 3.77 yen from 49.94 yen.Says the profit outlook lowered due to the costs in health care business and provisions of allowance for doubtful accounts.  Full Article